Protagonist Therapeutics, Inc.
PTGX
शेयरों में रैंक
#2248
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to... Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.
शेयर मूल्य
$139.76
मार्केट कैप
$9.04B
बदलाव (1 दिन)
1.28%
बदलाव (1 वर्ष)
86.35%
देश
US
व्यापार Protagonist Therapeutics, Inc. (PTGX)
श्रेणी
Healthcare
Protagonist Therapeutics, Inc. (PTGX) के लिए P/S अनुपात
October 2026 को P/S अनुपात TTM: 31.27
Protagonist Therapeutics, Inc. की नवीनतम वित्तीय रिपोर्ट और शेयर मूल्य के अनुसार, कंपनी का वर्तमान P/S अनुपात (TTM) 31.27 है। 2023 के अंत में, कंपनी का P/S अनुपात 21.69 था।
Protagonist Therapeutics, Inc. के लिए 2014 से 2026 तक P/S अनुपात का इतिहास
हर वर्ष के अंत में P/S अनुपात
| वर्ष | P/S अनुपात | परिवर्तन |
|---|---|---|
| 2026 (TTM) | 31.27 | 471.70% |
| 2024 | 5.47 | -74.78% |
| 2023 | 21.69 | 7.77% |
| 2022 | 20.13 | -65.24% |
| 2021 | 57.91 | 139.08% |
| 2020 | 24.22 | -96.93% |
| 2019 | 790.27 | 16,137.36% |
| 2018 | 4.87 | -73.47% |
| 2017 | 18.34 | 0.00% |
| 2016 | 0.00 | 0.00% |
| 2015 | 0.00 | 0.00% |
| 2014 | 0.00 | 0.00% |
समान कंपनियों या प्रतिस्पर्धियों के लिए P/S अनुपात
| कंपनी | P/S अनुपात | P/S अनुपात में अंतर | देश |
|---|---|---|---|
| 10.02 | -67.95% |
US
|
|
| 40.55 | 29.67% |
US
|
|
| 3.96 | -87.33% |
AU
|
|
| 10.15 | -67.55% |
NL
|
|
| - | - |
CH
|
